Mifegyne 200mg tablets – Changes to prescribing information
20/12/2022
Medicines for human use
Product information update (PIU)
This notice is to inform healthcare professionals about an update to prescribing information. In the case of medical termination of intrauterine pregnancy, a dose adjustment to a higher dose (600 mg) is advised where the patient is being treated concomitantly with CYP3A4 inducers.
Please see the document linked below for further information.
Product information
- Active substance
- Mifepristone
- Authorisation holder
- Nordic Pharma
- Authorisation number
- PA22946/001/001
- Human or veterinary medicine
- Human Medicine